EXCLUSIVE: Co-Diagnostics Completes Clinical and Analytical Studies of Upper Respiratory Point-of-Care Test Ahead Of FDA Submission Planned In Q3 2026

Benzinga Newsdesk www.benzinga.com Neutral 87.4%